Jupiter Asset Management Ltd. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10,455.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 144,402 shares of the company's stock after purchasing an additional 143,034 shares during the period. Jupiter Asset Management Ltd.'s holdings in Johnson & Johnson were worth $20,883,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in JNJ. Swedbank AB grew its position in shares of Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company's stock valued at $358,980,000 after purchasing an additional 111,570 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock valued at $562,723,000 after buying an additional 329,473 shares in the last quarter. United Bank increased its position in Johnson & Johnson by 5.6% during the 3rd quarter. United Bank now owns 3,788 shares of the company's stock worth $614,000 after buying an additional 202 shares during the period. Apollon Wealth Management LLC boosted its position in shares of Johnson & Johnson by 0.3% in the third quarter. Apollon Wealth Management LLC now owns 87,418 shares of the company's stock valued at $14,167,000 after acquiring an additional 279 shares during the period. Finally, Harbour Investments Inc. increased its holdings in shares of Johnson & Johnson by 28.8% during the third quarter. Harbour Investments Inc. now owns 36,150 shares of the company's stock worth $5,858,000 after purchasing an additional 8,077 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.
Insider Activity at Johnson & Johnson
In other news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.
Johnson & Johnson Trading Up 0.1 %
JNJ traded up $0.08 during trading on Thursday, reaching $162.93. 5,286,000 shares of the company's stock were exchanged, compared to its average volume of 7,084,071. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The firm has a fifty day moving average price of $154.60 and a two-hundred day moving average price of $156.38. The stock has a market capitalization of $392.28 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.29 earnings per share. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is currently 74.59%.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on JNJ. Citigroup cut their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Stifel Nicolaus decreased their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a report on Thursday, January 23rd. Raymond James cut their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Finally, StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $171.33.
View Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
